Dr. Michael D’Angelica (https://twitter.com/MichaelDAngeli2?s=20)is a surgical oncologist and hepatobiliary surgeon at Memorial Sloan Kettering Cancer Centre. He is world-renowned for both his research and clinical expertise in the treatment of colorectal liver metastases. We got to pick his brain on his approach to colorectal liver mets, as well as some of his broader advice for prospective fellows and his experience living in New York City though the COVID19 pandemic.Transcript: http://canjsurg.ca/podcast-episode-e61-masterclass-with-michael-dangelica-on-colorectal-liver-metastases/ Links:1. Hepatic resection for colorectal metastases – review by Tim Frankel and Dr. D’Angelica. https://pubmed.ncbi.nlm.nih.gov/24318723/2. Safety and feasibility of initiating a hepatic artery infusion pump chemotherapy program for unresectable colorectal liver metastases: A multicenter, retrospective cohort study. https://pubmed.ncbi.nlm.nih.gov/33095919/3. The re-birth of hepatic arterial infusion for colorectal liver metastases by Dr. Nancy Kemeny. https://jgo.amegroups.com/article/view/1042/html4. Assessing resectability of colorectal liver metastases: How do different subspecialties interpret the same data? https://pubmed.ncbi.nlm.nih.gov/30067183/5. Treatment sequencing for simultaneous colorectal liver metastases. Review by Dr. D’Angelica. https://pubmed.ncbi.nlm.nih.gov/30816577/Bio (from AHPBA website):Dr. D’Angelica is an Assistant Attending in the Department of Surgery, Hepatopancreatobiliary Service at Memorial SloanKettering Cancer Center. He is a Board-certified surgical oncologist with expertise in treating cancer of the liver, bile ducts, gall bladder, and pancreas. He works with a team that has developed and uses many surgical and non-surgical techniques that have shown remarkable success in treating these cancers. Sloan-Kettering’s multi-disciplinary methods of treatment — including novel combinations of surgery, ablation, embolization as well as systemic and regional chemotherapy — offer patients with cancers in these organs a good chance of long-term survival and cure.Dr. D’Angelica earned his M.D. at the Tufts University School of Medicine in 1993, followed by a residency at the University of Connecticut Integrated General Surgery through 2000. He did a Research Fellowship at Memorial Sloan-Kettering Cancer Center from 1995-97, serving as Chief Administrative Fellow in 1996-97. Dr. D’Angelica did his Clinical Fellowship at Sloan-Kettering form 2000 to 2002.Dr. D’Angelica belongs to several professional societies in addition to AHPBA, including the American College of Surgeons, Society of Surgical Oncology, the Society for Surgery of the Alimentary Tract, and the Uconn Surgical Society. He serves as a reviewer for several professional journals, including Surgery, Journal of the American College of Surgeons, Cancer, Pancreatology, and the Annals of Surgical Oncology.Dr. D’Angelica has a strong clinical interest in combining surgery, systemic chemotherapy, and hepatic arterial infusional chemotherapy (chemotherapy delivered directly to the liver through an implanted device) to treat tumors that have spread extensively throughout the liver. Dr. D’Angelica has published extensively on the treatment of metastatic colorectal cancer and proven that cure is possible with liver resection. He has been very involved in research on the treatments of gallbladder, pancreas, and bile duct cancer. Members of his research group are studying tissues from surgical specimens to identify genetic changes in tumors with the goal of improving treatment outcomes and enable us to develop new treatments.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related